As SPARC can also increase AKT phosphorylation, and as HSP27 and AKT interact to regulate the activity of each other, we proposed that inhibition of HSP27 may be a therapeutic approach to inhibit both SPARC-induced glioma cell invasion and survival. This evidence concerns the gene SPARC and central nervous system cancer.